Fan X, Li B, Zhang F, Liu M, Kwan H, Liu Z
Adv Sci (Weinh). 2024; 12(7):e2413525.
PMID: 39716892
PMC: 11831508.
DOI: 10.1002/advs.202413525.
Pessino G, Scotti C, Maggi M, Immuno-Hub Consortium
Cancers (Basel). 2024; 16(5).
PMID: 38473265
PMC: 10931414.
DOI: 10.3390/cancers16050901.
Zhu Y, Tang S, Yuan Q, Fu J, He J, Liu Z
Cell Rep Med. 2024; 5(2):101375.
PMID: 38278146
PMC: 10897507.
DOI: 10.1016/j.xcrm.2023.101375.
Xu J, Cui J, Jiang H, Zeng Y, Cong X
Cancer Med. 2023; 12(7):7762-7771.
PMID: 36622048
PMC: 10134273.
DOI: 10.1002/cam4.5532.
Park J, Choi J, Cao L, Mohanty J, Suzuki Y, Park A
Cell Rep. 2022; 41(4):111545.
PMID: 36288716
PMC: 9636537.
DOI: 10.1016/j.celrep.2022.111545.
A Novel Secreted Protein-Related Gene Signature Predicts Overall Survival and Is Associated With Tumor Immunity in Patients With Lung Adenocarcinoma.
Chen S, Zhang J, Li Q, Xiao L, Feng X, Niu Q
Front Oncol. 2022; 12:870328.
PMID: 35719915
PMC: 9204015.
DOI: 10.3389/fonc.2022.870328.
Fibroblast Growth Factor 19 Induced Changes in Non-malignant Cholangiocytes.
Yang J, Sontag D, Kung S, Minuk G
J Clin Transl Hepatol. 2021; 9(6):909-916.
PMID: 34966654
PMC: 8666367.
DOI: 10.14218/JCTH.2021.00087.
Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Yu Y, Shi X, Zheng Q, Wang X, Liu X, Tan M
Int J Biol Sci. 2021; 17(10):2576-2589.
PMID: 34326695
PMC: 8315028.
DOI: 10.7150/ijbs.58776.
Role of FGF15 in Hepatic Surgery in the Presence of Tumorigenesis: Dr. Jekyll or Mr. Hyde?.
Caballeria-Casals A, Mico-Carnero M, Rojano-Alfonso C, Maroto-Serrat C, Casillas-Ramirez A, Alvarez-Mercado A
Cells. 2021; 10(6).
PMID: 34200439
PMC: 8228386.
DOI: 10.3390/cells10061421.
Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer.
Liu Y, Wang C, Li J, Zhu J, Zhao C, Xu H
Front Pharmacol. 2021; 12:633453.
PMID: 33981224
PMC: 8107720.
DOI: 10.3389/fphar.2021.633453.
Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets.
Wang H, Yang J, Zhang K, Liu J, Li Y, Su W
Front Pharmacol. 2021; 12:650388.
PMID: 33935756
PMC: 8082422.
DOI: 10.3389/fphar.2021.650388.
Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.
Deng W, Chen X, Jiang K, Song X, Huang M, Tu Z
ACS Med Chem Lett. 2021; 12(4):647-652.
PMID: 33859803
PMC: 8040253.
DOI: 10.1021/acsmedchemlett.1c00052.
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Kanzaki H, Chiba T, Ao J, Koroki K, Kanayama K, Maruta S
Sci Rep. 2021; 11(1):5303.
PMID: 33674622
PMC: 7935880.
DOI: 10.1038/s41598-021-84117-9.
FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
Huynh H, Prawira A, Le T, Vu T, Hao H, Huang A
Exp Mol Med. 2020; 52(11):1857-1868.
PMID: 33235319
PMC: 8080677.
DOI: 10.1038/s12276-020-00524-4.
Inflammatory Markers in Suction Blister Fluid: A Comparative Study Between Interstitial Fluid and Plasma.
Sjobom U, Christenson K, Hellstrom A, Nilsson A
Front Immunol. 2020; 11:597632.
PMID: 33224151
PMC: 7670055.
DOI: 10.3389/fimmu.2020.597632.
Dual Role of MSC-Derived Exosomes in Tumor Development.
Zhao R, Chen X, Song H, Bie Q, Zhang B
Stem Cells Int. 2020; 2020:8844730.
PMID: 32963552
PMC: 7499322.
DOI: 10.1155/2020/8844730.
Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.
Liu Y, Cao M, Cai Y, Li X, Zhao C, Cui R
Front Cell Dev Biol. 2020; 8:95.
PMID: 32154250
PMC: 7044267.
DOI: 10.3389/fcell.2020.00095.
Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.
Maeda T, Kanzaki H, Chiba T, Ao J, Kanayama K, Maruta S
BMC Cancer. 2019; 19(1):1088.
PMID: 31718608
PMC: 6849282.
DOI: 10.1186/s12885-019-6322-9.
Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis.
Gadaleta R, Scialpi N, Peres C, Cariello M, Ko B, Luo J
Sci Rep. 2018; 8(1):17210.
PMID: 30464200
PMC: 6249240.
DOI: 10.1038/s41598-018-35496-z.
Blocking FGFR4 exerts distinct anti-tumorigenic effects in esophageal squamous cell carcinoma.
Xin Z, Song X, Jiang B, GongSun X, Song L, Qin Q
Thorac Cancer. 2018; 9(12):1687-1698.
PMID: 30267473
PMC: 6275831.
DOI: 10.1111/1759-7714.12883.